Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for July 2012
July 2, 2012
- GSK and Theravance Announce Positive Results From Four Pivotal Phase III Studies for Once-Daily LAMA/LABA (UMEC/VI) in COPD
- Prochymal Significantly Reduces Hypertrophy, Arrhythmia and Progression to Heart Failure in Patients Suffering a Heart Attack
- Myelodysplastic Syndromes (MDS) Linked to Abnormal Stem Cells
- Protalix BioTherapeutics Announces New Clinical Data on taliglucerase alfa Presented at the 10th Annual European Working Group on Gaucher Disease Meeting
- Israeli Channel 2 reports: Dramatic Change in Patient with ALS and MG following Compassionate Use of BrainStorm's NurOwn? Cell Therapy
- Analysis of Krystexxa Phase III Data Demonstrates Improved Health-Related Quality of Life and Physical Function in Refractory Chronic Gout Patients
- Scientists at Children's Hospital Los Angeles Identify Mechanism Critical to Lung Formation and Regeneration
July 3, 2012
- Diamyd Medical Reports Results from Phase II Study in Cancer Pain
- Study Examines Fingolimod Therapy in Patients with Multiple Sclerosis
- PNAS Publishes OncoMed Data Demonstrating Potent Anti-Cancer Activity for Novel Wnt Pathway Antibody OMP-18R5
- Stem Cell Therapy Shown to be Effective in Treating Liver Cirrhosis
July 5, 2012
- Cancer Therapeutics Reveals Proof of Concept for Second Development Drug
- MorphoSys Partner OncoMed Publishes Data on HuCAL Antibody OMP-18R5
- Merck: EXPAND Trial of Erbitux in Advanced Gastric Cancer Does Not Meet Primary Endpoint
- Receipt of Shingles Vaccine Among Patients With Diseases Like Psoriasis and Rheumatoid Arthritis Not Associated With Increased Risk of Shingles
July 6, 2012
July 9, 2012
- HPV vaccine reduces infection, even in unvaccinated
- Epidermal Growth Factor Inhibits Colitis-Associated Cancer
- Eisai Announces Preliminary Results of Phase III Study of Halaven (eribulin mesylate) Injection in Locally Advanced or Metastatic Breast Cancer
- Tonix Pharmaceuticals Reports Positive Preclinical Data on Sublingual TNX-102
- ACADIA Pharmaceuticals Reports Promising Effects of Pimavanserin in Preclinical Model of Alzheimer's Disease Psychosis
- Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
- Anavex to present at Alzheimer's Association International Conference
- Highlights of significant results on Orally administered Optina for Diabetic Macular Edema (DME), including results for visual acuity.
July 10, 2012
- Pergamum Rreports Top Lline Phase II-data from the Clinical Trial for Prevention of Post-Surgical Adhesions
- PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
- Researcher Discovers Micro RNA Required for the Growth and Spread of Cancer
July 11, 2012
- Alnylam Presents New Pre-clinical Data with its RNAi Therapeutic Program in Hemophilia
- Announcement of topline results from the GLACIER study
- Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
- Shionogi-ViiV Healthcare Announces Positive Initial Data From Phase III Study of Dolutegravir-Based Regimen Vs Atripla in HIV
- Theravance Announces Positive Topline Results From TD-1211 Phase 2b Study 0084 for the Treatment of Opioid-Induced Constipation
- World's First Intensive Study of Postpartum Women with von Willebrand Disease Shows Potential Risk of Delayed Hemorrhage, Despite Treatment
- Publication of PrEP Trial Data Provides Clear Evidence that PrEP Works for Men and Women
- FHI 360: Final Results Of FEM-PrEP HIV-Prevention Study Indicate Great Attention To Adherence Will Be Required In PrEP Programs
July 12, 2012
- Update on Phase III Trial for Odanacatib, Merck's Investigational Cat-K Inhibitor for Osteoporosis
- Verastem Discloses Research Results and Updated Clinical Plans at Research and Development Day
- Clinical Data Finds Strong Association between HDL Particles and Coronary Heart Disease
- ACT Announces First Stargardt Patient Treated With Higher Dosage of Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells
- Quintiles Global Commercial Solutions Expands to Brazil
July 13, 2012
- Synexus Further Expands Its Presence in South Africa
- Apremilast achieves clinically meaningful and statistically significant improvement in measures of both signs and symptoms and physical function
- Ember Therapeutics Announces Cell Publication of Key Beige Fat Discovery; Technology Licensed from the Dana-Farber Cancer Institute
- Merck Highlights Data Presentations at the Alzheimer's Association International Conference, 2012
- Cancer Cell Article Demonstrates First Definitive Evidence for Targeting of Pol I as New Approach to Cancer Therapy
- Bayer HealthCare to Present Data on Secondary Prophylaxis with Kogenate(R) FS -- antihemophilic factor (recombinant) on Bleeding Frequency in Adults and Adolescents with Severe Hemophilia A
- Kala Pharmaceuticals Co-founder Publishes Data on Novel Therapeutic Approach to Overcome Mucosal Barrier for Prevention of Herpes Simplex Virus-2 Infection
- Satori Pharmaceuticals to Present Data Highlighting Promise of Gamma-Secretase Modulators in Treatment of Alzheimer's Disease
- No Differences in Quality of Clinical Trial Data Across Regions, Reports Drug Information Journal
July 16, 2012
- Preliminary Results Demonstrate That the Novel Delivery of Dexamethasone via Mercator's Platform Micro-Infusion Catheter Inhibits Restenosis for at Least 9 Months in 10 Patients Treated for Peripheral Vascular Disease (PAD)
- Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
- Tekmira's LNP Technology Enables Alnylam's Positive ALN-TTR02 Clinical Data
- Amnestic Mild Cognitive Impairment (MCI) Doubles Risk of Death
- New Model Of Alzheimer's Derived From Skin Cells Of People With The Disease
- Alnylam Reports Positive ALN-TTR02 Clinical Data, with Robust Knockdown of Serum Transthyretin (TTR) of up to 94% After Single Dose
July 17, 2012
July 18, 2012
- Treatment of Multiple Sclerosis With Interferon Beta Is Not Associated With Less Progression of Disability
- Alzheimer's Treatment Study Reports Three Years with No Decline in Memory and Function at AAIC 2012
- ACRO Statement on European Commission's Proposal for Clinical Trials Regulation
- EnVivo Pharmaceuticals Announces Statistically Significant Improvement in Cognition and Clinical Function in Phase 2b Clinical Trial in Alzheimer's Disease
- Doctors and Rheumatoid Arthritis Patients Differ on Perception of Disease Activity
- New Results From Four Alzheimer's and Dementia Clinical Trials Highlight "Developing Topics" Reports at AAIC 2012
- Nymox Announces Positive Safety Monitoring Committee Results for Phase 3 BPH NX02-0020 Repeat Injection U.S. Study
July 19, 2012
- Actinium Pharmaceuticals Successfully Completes First Cohort in Multicenter Phase I/II Leukemia Trial of Actimab-A
- Favorable July 12 Safety Monitoring Committee Meeting for Nymox Pivotal Phase 3 NX-1207 Trials
- Favorable July 12 Safety Monitoring Committee Meeting for Nymox Pivotal Phase 3 NX-1207 Trials
- Anavex presents compelling data at world?s largest Alzheimer?s conference
- ERT Granted Patents on Clinical Trial Participant Compliance
- Sarepta's Marburg Virus Drug Shows Survival in Primates Despite Delayed Treatment
- PAREXEL And Korea Drug Development Fund Announce Alliance To Accelerate Global Drug Development And Commercialization
- Addex Announces the Publication of Positive Data on the Efficacy of mGluR4 Positive Allosteric Modulator in Parkinson's Disease Pre-Clinical Models
- ISR Reports: PPD Receives Top Marks for Customer Loyalty and Value in Phase I
- Max Planck Institute Presents Study Positioning Biovest Bioreactor Systems as Potential Novel Viral Vaccine Manufacturing Platform
- to-BBB presents and publishes data on 2B3-201 for neuroinflammation and receives Innovation Credit for product development
- Venture-Backed Life Science Companies Hit 7 Year Highs in Large Acquisitions
- ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
- AMRI India Receives Silver Shield Award from Abbott Health Care Pvt. Ltd.
- BRISK-FL Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Does Not Meet Overall Survival Primary Endpoint
July 20, 2012
- ICON Shareholders Vote in Favour of All Resolutions at Its Annual General Meeting
- Dollar Volume of Health Care Mergers and Acquisitions Doubles in Second Quarter 2012 According to New Report from Irving Levin Associates, Inc.
- WorldOne acquires Sermo
- Data Underscore Promise of Satori Pharmaceuticals' Gamma-Secretase Modulator Program in Treatment of Alzheimer's Disease
- ISR Reports: PPD Receives Top Marks for Customer Loyalty and Value in Phase I
- Parexel and Korea Drug Development Fund Announce Alliance to Accelerate Global Drug Development and Commercialization
- Shire?s Advanced BioHealing Renamed Shire Regenerative Medicine
- AMAG Pharmaceuticals Announces Positive Preliminary Results from its Phase III Study Evaluating Feraheme Compared to Placebo in Patients with Iron Deficiency Anemia
- ClinPlan Chooses BioClinica Optimizer for Clinical Supply Chain Simulation
- NABP Stresses Need for International Collaboration to Combat Online Counterfeit Drug Distribution
- BIO Praises Rep. Michael Fitzpatrick on Introduction of Fostering Innovation Act
- Clinipace Worldwide Selected to Manage Prometheus Laboratories Oncology Program
- Provectus Pharmaceuticals' PV-10 Data to Be Presented at ESMO 2012 on October 1, 2012
- Alzheimer's Treatment Study Reports Three Years With No Decline In Memory And Function At AAIC 2012
- Final Phase 3 Results for GE Healthcare Investigational Imaging Agent Flutemetamol Presented at Alzheimer's Association International Conference
- Clinical Site Services' Chris Trizna Contributing Author in Diana Anderson-Foster's Newest Release 'Global Issues in Patient Recruitment and Retention'
July 23, 2012
- Head-to-Head Study Comparing Navidea's AZD4694 to the Gold Standard for Imaging Beta Amyloid Protein Deposits Presented at Alzheimer's Association International Conference
- Depomed Announces Publication of Phase 3 Data from Gralise (gabapentin) Clinical Trial
- Addition of Tarceva (erlotinib) to Nexavar (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
- Pfizer Reports Top-Line Results of EU Post-Authorization Safety and Efficacy Study of Lyrica's Discontinuation Effects In Patients with Generalized Anxiety Disorder
- InVivo Therapeutics' CEO Frank Reynolds Scheduled to Appear on Bloomberg-TV to Discuss Spinal Cord Injury and Pain Treatments
- IFPMA, BIO and WADA Advance Anti-Doping Collaboration with the Launch of 2 FIELDS 1 GOAL Campaign
- BrainStorm Reports Outstanding ALS Interim Clinical Trial Results
- Sandoz completes acquisition of Fougera Pharmaceuticals, positioning Sandoz as #1 in generic dermatology globally
- Pfizer Reports Top-Line Results of Study of Lyrica's Effect on Male Reproduction Conducted as a Post-Approval Commitment Required by the U.S. Food and Drug Administration
- Greyson International, Inc. Receives Notice of Allowance from the U.S. Patent and Trademark Office for its Breakthrough Trilexon® Delivery System Technology
- ISENTRESS (raltegravir) in Combination Therapy Demonstrated Long-Term Efficacy, Safety and Tolerability in Previously Untreated Adult Patients with HIV-1 for up to 240 Weeks
- Pharmacokinetic Study Results Released Evaluating Interactions Between LIVALO(R) (pitavastatin) and Protease Inhibitor Combination (darunavir/ritonavir) in Healthy Volunteers
- NanoViricides Retains a Consulting Firm to Expedite First FluCide Human Trials in Australia
- Hyperion Therapeutics IPO Criticized for Poor Corporate Governance by UNITEHERE
- Ahmed D. Hussein Files Definitive Proxy Materials with SEC
- Quality Systems Management Team Sends Letter to Shareholders in Support of Company Board Nominees
- Quality Systems Sends Shareholder Letter Detailing Significant Concerns Regarding Ahmed Hussein's Proxy Solicitation
- ACGT, Inc. to Provide Overnight DNA Sequencing Services to Chicago-Based Researchers
- Ronald L. Chez Files Amended 13D and Letter to the Board
- Bausch + Lomb Commences Tender Offer of Its 9 7/8% Senior Notes due 2015 (CUSIP Nos. 071707AN3 and U07190AA6)
- Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
- Leading India-USA based CRO Announces Data Management/EDC, Medical Writing Milestone
- Pharma IQ's Laboratory Informatics Report: Current Trends & Predictions for 2015
- AAAS To Host Live Online Discussion On 2013 U.S. Federal R&D Budget
July 24, 2012
- Pfizer Reports Top-Line Results of EU Post-Authorization Safety and Efficacy Study of Lyrica?s Discontinuation Effects In Patients with Generalized Anxiety Disorder
- BioCryst Announces Positive Results from Two Ulodesine Phase 2 Trials in Patients with Gout
- New York Genome Center Announces Location of World-Class Facility for Sequencing, Bioinformatics, and ?Big Data? Warehousing
- Elan Announces Pfizer's Release of A Top-Line Result In First Of Four Bapineuzumab Phase 3 Trials
- Pfizer Announces Topline Results of First of Four Studies in Bapineuzumab Phase 3 Program
- Cure Duchenne Supported Sarepta Therapeutics Research Study for the Treatment of Duchenne Muscular Dystrophy
July 25, 2012
- Gilead's HIV Integrase Inhibitor Elvitegravir Dosed Once Daily as Effective as Twice-Daily Raltegravir Over Two Years of Therapy in Pivotal Phase 3 Study
- Novavax Provides Update on Influenza Programs
- Gilead's Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study
- Gilead's Once-Daily Single Tablet Regimen Complera® Maintains HIV Suppression Among Patients Switching From Protease Inhibitor-Based Regimens
- Texas A&M Biologists Prove ZOLOFT Packs Potential to Fight Fungal Meningitis
- Onyx Pharmaceuticals Announces Kyprolis Study Published in the Medical Journal Blood
- Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
- Parexel Launches the Parexel Biopharm Unit to Meet the Critical Development Goals of Small and Mid-Sized Biopharmaceutical Companies
- PRA Participates in Landmark Alzheimer?s Prevention Clinical Trial
July 26, 2012
- Merck, Collaborators Publish Study Showing Potential for Eradication of Persistent HIV Virus in the Body
- Neurology Publishes Results From Pivotal Study Of Eisai's Perampanel
- Apogenix GmbH: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial in Treatment of Recurrent Glioblastoma
- Spectrum Pharmaceuticals Announces Publication Demonstrating Enhanced Survival with ZEVALIN in Premier Medical Journal Blood
- Apogenix: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial in Treatment of Recurrent Glioblastoma
- FyMed Demonstrates Superiority of FY101C over Ibuprofen and Naproxen in the Treatment of Pain and Inflammation
- Lymphoseek Data Presented by Independent Investigators at 8th International Conference on Head and Neck Cancer
- Ricerca Biosciences Launches Two New Preclinical Assay Services
- Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardium's New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart
- Protalex, Inc. Findings from Phase 1b Dose Escalation Study of PRTX-100 in Patients with Active Rheumatoid Arthritis
- TB on the Rocks? New Drug Cocktail Shows Great Promise
- Ricerca Biosciences Launches Two New Preclinical Assay Services
July 27, 2012
- Genentech Reports Second Positive Study of ACTEMRA Given by Subcutaneous Injection to Patients with Rheumatoid Arthritis
- ViroPharma's Cinryze (C1 esterase inhibitor [human]) Open Label Prophylaxis Study Showed Up To 2.6 Years Of Effectiveness In Majority Of Subjects With Hereditary Angioedema
- Community-wide Consensus Process Generates a Framework for Reporting of T-cell Experiments in Clinical Immunology
July 30, 2012
- Auxilium Pharmaceuticals, Inc. Announces Positive Top-line Data from Phase IIIb Dupuytren's Contracture Multicord Study
- Tonix Pharmaceuticals Announces Completion of Clinical Trial of Sublingual TNX-102
- New Research from the Trudeau Institute Holds Promise for Cancer Immunotherapy Treatments
- Advaxis Reports Updated Phase 2 Cervical Cancer Trial Data at NCI/GOG Meeting
- Cannabis Science Releases New Photos on the Continual Improvement of Patient Three Who Suffers from Squamous Cell Carcinoma
- Pooled Analysis Showed Onglyza (saxagliptin) Provided Improvements in Key Measures of Blood Sugar Control in Adults with Type 2 Diabetes at High Risk for CV Disease
- Increase in Genomic Replikin Counts Predicted Recent Avian Flu (H5N1) Outbreak in Cambodia
- Vertex Announces Positive Results from Viral Kinetic Study of the Nucleotide Analogue ALS-2200 in People with Hepatitis C
